Altu-238
ALTU-238
ALTU-238 is a crystallized formulation of hGH that is designed to be administered once weekly through a fine gauge needle for the treatment of hGH disorders in both pediatric and adult populations. Pediatric growth hormone deficiency affects approximately 1 in 3,500 children and 1 in 10,000 adults. The market for hGH was approximately $2.4 billion in 2005. Secondary indications may include small for gestational age, idiopathic short stature, Turner Syndrome, HIV-AIDS, Prader-Willi Syndrome, and short bowel syndrome.
ALTU-238 is a long-acting formulation that will be designed to require fewer injections without the use of polymers or fusion proteins; a significant improvement in development. There are currently 8 FDA-approved human growth products on the market in the U.S. All the products on the market are essentially identical and are differentiated solely through variations in their respective delivery devices and formulations. ALTU-238 has completed a Phase II clinical trial in adults with growth hormone deficiency. ALTU-238 will be developed and commercialized under an exclusive strategic collaboration between Altus and Genentech, Inc.
__________________
REDUCING THE WORLD TO THE SIZE OF A DIME.- OPUS
|
11-11-2007, 02:44 AM
Linear Mode
